# Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

> **NCT05825417** · PHASE4 · RECRUITING · sponsor: **Sheffield Teaching Hospitals NHS Foundation Trust** · enrollment: 40 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Selexipag
- **DRUG:** Riociguat
- **DEVICE:** CardioMEMS pulmonary artery pressure monitor
- **DEVICE:** Confirm Rx

## Key facts

- **NCT ID:** NCT05825417
- **Lead sponsor:** Sheffield Teaching Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-14
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05825417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05825417, "Pulmonary Hypertension: Intensification and Personalisation of Combination Rx". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05825417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*